

PRESS RELEASE

Biocon Biologics Recognized as an Asia IP Elite for 2023, IPR Team adjudged as the Team of the Year

Bengaluru, Karnataka, India, December 15, 2023

Biocon Biologics Limited, a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced today that the Company has been again recognized as an **Asia IP Elite for 2023** by IAM (Intellectual Asset Management), the world's biggest IP publication. Biocon Biologics has been awarded this prestigious accolade reserved for a select group of Asia-based corporations and research institutions that are leading the region in intellectual property value creation.

In 2019, Biocon Biologics made its debut on this prestigious list for its robust IP management and consistent IP value creation. This is the seventh consecutive year for Biocon and subsequently its subsidiary Biocon Biologics to make it to this prestigious list.

Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list. In addition, the Company's IPR team has been adjudged as the '**Healthcare and Biotechnology Team of the Year**' from Asia for 2023.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said:

"We are honoured to receive this prestigious award for the seventh time. This is a recognition of our commitment to innovation and creation of intellectual capital. I am very proud of our IP Team and would like to congratulate them on this remarkable achievement. Biocon Biologics remains committed to leveraging science to drive affordable innovation for the benefit of patients worldwide."

Biocon Biologics is leveraging its robust in-house IP strategy and capabilities to enable early entry of biosimilar products to meet patients' needs for affordable therapy in global markets.

The editorial team of IAM inducts an exclusive group of companies into the Asia IP Elite every year based on an assessment of their innovative approaches to extracting value from IP. Asia IP Elite members are chosen for adhering to the following criteria:

- Placing IP strategy at the centre of its business.
- Obtaining demonstrable, significant and ongoing value from intellectual property as a direct result of the strategies it employs.

- Possessing a senior management that understands the operational and strategic importance of intellectual property.
- Constantly reappraising and improving its IP strategy in order to take advantage of market developments.

This year, 88 entities from India, China, Japan, South Korea, Malaysia, Thailand, Taiwan, Australia, New Zealand, and Singapore featured on the list.

Adjudging Biocon Biologics' IPR team as the '**Healthcare and Biotechnology Team of the Year**' from Asia, IAM said: "These are given to executives and IP departments that we feel, based on publicly available information and market feedback, deserve special recognition for their contributions to their organisations over past year."

About Biocon Biologics Ltd.

Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to high quality biosimilars for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. The Company has acquired the global biosimilars business of its long-standing partner Viatrix, which is a historic milestone in its value creation journey. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. It has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, BBL is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on Twitter: [@BioconBiologics](https://twitter.com/BioconBiologics) and LinkedIn: [Biocon Biologics](https://www.linkedin.com/company/biocon-biologics) for company updates.

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com; Follow-us on Twitter: [@bioconlimited](https://twitter.com/bioconlimited) for company updates.

CONTACTS:	
MEDIA	
Seema Ahuja Global Head of Communications & Corporate Brand Biocon Group & Biocon Biologics +91 99723 17792 seema.ahuja@biocon.com	Anugya Sinha Manager, Global Communications Biocon Group +91 99726 88887 anugya.sinha@biocon.com